Aripiprazole augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive–compulsive disorder: a 12-week open-label preliminary study
The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
One of the most studied and well-documented strategies for treatment-resistant obsessive-compulsive disorder (OCD) is the addition of antipsychotic drugs to the ongoing serotonin reuptake inhibitor (SRI) treatment. To date, there has been a paucity of data regarding the use of aripiprazole in OCD patients who failed to respond to SRIs. The aim of the present pilot study was to investigate the efficacy of flexible doses of aripiprazole as augmenting agent in the treatment of resistant OCD patients. Patients meeting the inclusion criteria of treatment-resistant OCD entered a 12-week, open-label, flexible-dose trial of aripiprazole addition to SRIs. Aripiprazole was started at 5 mg/day and increased up to a maximum of 20 mg/day. Twelve patients fulfilled entry criteria; nine patients took at least one dose of study medication and eight of them completed the study. The mean daily dosage of aripiprazole in completers was 11.2+/-5.2 mg/day. Patients showed a significant improvement over the 12-week study period (paired t-test for mean Yale-Brown Obsessive Compulsive Scale total score at week 12 as compared with baseline - all patients: t = 4.860, d.f. = 8, P = 0.001). The most common adverse event reported was inner unrest reported by four (44.4%) patients. Our study supports the notion that adding aripiprazole to SRIs could be a valid strategy for treatment-resistant OCD patients, and points towards the need of randomized, double-blind studies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Yale-Brown Obsessive Compulsive Scale: II. Validity
Goodman, W. K. (1989) · Archives of General Psychiatry · doi:10.1001/archpsyc.1989.01810110054008 · Cited by 2,799 · cited 2×
“The primary efficacy measures were the Y-BOCS total score (Goodman et al., 1989a, 1989b) and the Clinical Global Impression-Severity (CGI-S) score (Guy, 1987), which were completed at baseline and every 2 weeks.”
MethodLingjærde, O., Ahlfors, U. G., Bech, P., Dencker, S. J., & Elgen, K. (1987) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1987.tb10566.x · Cited by 1,705 · cited 3×
“The UKU Side Effect Rating Scale.”
MethodInfluentialBloch, M. H., Landeros-Weisenberger, A., Kelmendi, B., Coric, V, Bracken, M. B., & Leckman, J. F. (2006) · Molecular Psychiatry · doi:10.1038/sj.mp.4001823 · Cited by 635 · cited 3×
“…and larger trials, as differences might exist between different antipsychotics (Bloch et al., 2006; Ipser et al., 2006; Skapinakis et al., 2007): Bloch et al. (2006), for example, concluded that there is sufficient evidence showing the efficacy of haloperidol and risperidone, whereas the…”
BackgroundMcDougle, C. J., Epperson, C. N., Pelton, G. H., Wasylink, S., & Price, L. H. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.8.794 · Cited by 571 · cited 1×
“…and the second-generation antipsychotics such as risperidone, olanzapine and quetiapine, proved to be effective in several double-blind studies (McDougle et al., 1994, 2000; Bystritsky et al., 2004; Denys et al., 2004; Erzegovesi et al., 2005), although negative double-blind studies also exist…”
BackgroundDenys, D., de Geus, F., van Megen, H. J. G. M., & Westenberg, H. G. M. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0803 · Cited by 248
Bystritsky, A., Ackerman, D. L., Rosen, R. M., Vapnik, T., Gorbis, E., Maidment, K. M., & Saxena, S. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0418 · Cited by 220 · cited 1×
“…antipsychotics such as risperidone, olanzapine and quetiapine, proved to be effective in several double-blind studies (McDougle et al., 1994, 2000; Bystritsky et al., 2004; Denys et al., 2004; Erzegovesi et al., 2005), although negative double-blind studies also exist for risperidone (Hollander…”
BackgroundHollander, E., Rossi, N. B., Sood, E., & Pallanti, S. (2003) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145703003730 · Cited by 197 · cited 2×
“…et al., 1994, 2000; Bystritsky et al., 2004; Denys et al., 2004; Erzegovesi et al., 2005), although negative double-blind studies also exist for risperidone (Hollander et al., 2003), olanzapine (Shapira et al., 2004) and quetiapine (Carey et al., 2005; Fineberg et al., 2005; Kordon et al., 2008).”
BackgroundResultInfluentialCarey, P. D., Vythilingum, B., Seedat, S., Muller, J. E., van Ameringen, M., & Stein, D. J. (2005) · BMC Psychiatry · doi:10.1186/1471-244x-5-5 · Cited by 133
Fineberg, N. A., Sivakumaran, T., Roberts, A., & Gale, T. (2005) · International Clinical Psychopharmacology · doi:10.1097/00004850-200507000-00005 · Cited by 105
Cited by
Katzman, M. A., Bleau, P., Blier, P., Chokka, P., Kjernisted, K., Van Ameringen, M., & the Canadian Anxiety Guidelines Initiative Group on behalf of the Anxiety Disorders Association of Canada/Association Canadienne des troubles anxieux and McGill University (2014) · BMC Psychiatry · doi:10.1186/1471-244x-14-s1-s1 · Cited by 1,090
“Adjunctive aripiprazole [750-755] 1 Benzodiazepines”
BackgroundEvidence-based pharmacotherapy of obsessive-compulsive disorder
Fineberg, N. A., Brown, A., Reghunandanan, S., & Pampaloni, I. (2012) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711001829 · Cited by 336
Fineberg, N. A., Hollander, E., Pallanti, S., Walitza, S., Grünblatt, E., Dell’Osso, B. M., Albert, U., Geller, D. A., Brakoulias, V., Janardhan Reddy, Y. C., et al. (2020) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000314 · Cited by 161
Self-citationPharmacotherapy of obsessive–compulsive disorder: evidence-based treatment and beyond
Fineberg, N. A., Reghunandanan, S., Brown, A., & Pampaloni, I. (2013) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867412461958 · Cited by 122
“A small open-label pilot study (Pessina et al., 2009) explored the efficacy of flexible doses of aripiprazole (< 20 mg) in 12 SRI-resistant patients.”
BackgroundMuscatello, M. R. A., Bruno, A., Pandolfo, G., Micò, U., Scimeca, G., Romeo, V. M., Santoro, V., Settineri, S., Spina, E., & Zoccali, R. A. (2011) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31820e3db6 · Cited by 122
“3%) met response criteria of 25% improvement or greater; 2 of them had a reduction 35% or greater in Y-BOCS total score versus baseline.(36) On the basis of these findings, the present study was aimed to test whether aripiprazole would be more effective than placebo on clinical symptoms and cognitive functioning in a…”
Result
Metadata
- Authors
- Pessina, E., Albert, U., Bogetto, F., & Maina, G.
- Venue
- International Clinical Psychopharmacology
- Published
- 2009-09
- Volume
- 24
- Issue
- 5
- Pages
- 265-269
- ISSN
- 0268-1315 (ISSN-L)
- OpenAlex
- W2168815673
- Cited by
- 71
- References
- 9
- FWCI
- 9.79
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Aripiprazole augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive–compulsive disorder: a 12-week open-label preliminary study. https://app.cochat.ai/papers/10.1097/yic.0b013e32832e9b91
- The paper
- Pessina, E., Albert, U., Bogetto, F., & Maina, G. (2009). Aripiprazole augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive–compulsive disorder: a 12-week open-label preliminary study. International Clinical Psychopharmacology. https://doi.org/10.1097/yic.0b013e32832e9b91
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.